On August 28, 2026, a status update was recorded for a clinical trial involving triptorelin, an LHRH agonist. The study, titled "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer," is registered under identifier NCT04557059.
The trial is a Phase 3 study and is currently listed as active but not recruiting. This status indicates that the trial is ongoing and that participant enrollment is not currently open. The trial examines the addition of apalutamide to a treatment regimen that includes radiotherapy and an LHRH agonist in patients with high-risk hormone-sensitive prostate cancer.
No results have been reported as part of this update. The change reflects only the trial's current recruitment and operational status as of the date listed. Triptorelin remains an approved compound, and this update does not include any new safety, efficacy, or outcome data.
Readers interested in learning more about triptorelin, including its approved uses and general background, can consult the compound overview for further context.